Abbott (NYSE: ABT) grants EVP stock options and performance shares

Rhea-AI Filing Summary

ABBOTT LABORATORIES executive Daniel Gesua Sive Salvadori reported awards of equity-based compensation. He received an option to buy 89,226 Abbott shares at an exercise price of $0.00 per share under the 2017 Incentive Stock Program, with the option becoming exercisable in three equal annual installments of 29,742 shares on February 24, 2027, February 24, 2028, and February 24, 2029. He also acquired 21,644 common shares as a performance-based restricted stock award with a three-year term, where no more than one-third of the award can vest in any one year, subject to Abbott reaching a minimum return on equity target, and the award allows shares to be withheld to cover taxes.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Salvadori Daniel Gesua Sive

Role EVP AND GROUP PRESIDENT

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	89,226	$0.00	--
Grant/Award	Common shares without par value	21,644	$0.00	--

Holdings After Transaction: Option (right to buy) — 89,226 shares (Direct); Common shares without par value — 153,877 shares (Direct)

Footnotes (1)

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,742 on February 24, 2027, 29,742 on February 24, 2028, and 29,742 on February 24, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salvadori Daniel Gesua Sive

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP AND GROUP PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		21,644(1)	A	$0	153,877	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(2)	$114.6	02/24/2026		A		89,226		02/24/2027	02/23/2036	Common Shares	89,226	$0	89,226	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,742 on February 24, 2027, 29,742 on February 24, 2028, and 29,742 on February 24, 2029.

	/s/ Daniel Gesua Sive Salvadori by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Abbott (ABT) report for Daniel Gesua Sive Salvadori?

Abbott reported that EVP and Group President Daniel Gesua Sive Salvadori received an option for 89,226 shares and a performance-based restricted stock award of 21,644 common shares, both granted under the Abbott Laboratories 2017 Incentive Stock Program.

How do the new Abbott (ABT) stock options for Daniel Gesua Sive Salvadori vest?

The employee stock option for 89,226 Abbott shares vests in three equal annual increments of 29,742 shares on February 24, 2027, February 24, 2028, and February 24, 2029, as specified under the Abbott Laboratories 2017 Incentive Stock Program.

What are the terms of the performance-based restricted stock award Abbott (ABT) granted?

The 21,644-share performance-based restricted stock award has a three-year term, with no more than one-third vesting in any year. Vesting depends on Abbott reaching a minimum return on equity target and includes the right to have shares withheld to satisfy tax obligations.

Does the Abbott (ABT) Form 4 show a stock purchase or a compensation grant?

The Form 4 reflects equity compensation grants, not open-market stock purchases. It reports a granted employee stock option and a performance-based restricted stock award to executive Daniel Gesua Sive Salvadori under the Abbott Laboratories 2017 Incentive Stock Program.

What program governs the new equity awards to the Abbott (ABT) executive?

Both the stock option and the performance-based restricted stock award were granted under the Abbott Laboratories 2017 Incentive Stock Program, which provides for equity-based compensation such as options and restricted shares to Abbott employees and executives.

Are the Abbott (ABT) equity awards to Daniel Gesua Sive Salvadori immediately exercisable or vested?

The 89,226-share stock option is not immediately exercisable and becomes exercisable in three annual tranches starting February 24, 2027. The 21,644 restricted shares vest over a three-year term, subject to a minimum return on equity target.